News

People with idiopathic pulmonary fibrosis (IPF) are at increased risk of several cancers other than lung cancer, a new study reports. The study, “Risk of cancer incidence in patients with idiopathic pulmonary fibrosis: A nationwide cohort study,” was published in the journal Respirology. IPF and…

Conditions affecting the heart, stomach, and esophagus occur more frequently in patients whose diagnosis of idiopathic pulmonary fibrosis (IPF) is delayed, coming more than one year after the onset of symptoms, according to a recent study. This delayed diagnosis seems, however, to have no impact on the risk of…

A three-year pulmonary rehabilitation program — a combination of aerobic, resistance, and breathing exercises — helped to maintain lung and muscle strength before a double-lung transplant in a middle-aged man with idiopathic pulmonary fibrosis (IPF) and a sedentary lifestyle, a case study reports. The study “Long-Term…

Biognosys and Boehringer Ingelheim are working together to expand the use of cutting-edge technologies for large-scale protein analysis in drug discovery, beginning with a study of potential new treatment approaches to idiopathic pulmonary fibrosis (IPF). Biognosys announced that it will bring its expertise in proteomics — the…

Failure of organs other than the lungs can be a predictor of mortality risk in people hospitalized due to acute exacerbations of idiopathic pulmonary fibrosis (IPF), a study reported. Elevated levels of C-reactive protein, a sign of inflammation, is also a risk factor for in-hospital mortality in these patients.

Researchers have discovered the existence of unique subtypes of epithelial cells in the lungs of people with pulmonary fibrosis (PF) that may drive tissue scarring, or fibrosis. Their findings were published in the study, “Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary…

The European Commission has approved Boehringer Ingelheim‘s Ofev (nintedanib) for the treatment of progressive fibrosing interstitial lung diseases (ILDs) in adults. The approval follows a recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP), as well as…